Kymera Revenue Drops 55 Percent in Q2
Kymera Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $78.47
+4.2% in 7d after detection
Post-detection moves
1h
—
1d
+3.2%
3d
+1.0%
7d
+4.2%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS